Skip to main content

Table 1 Clinicopathological and molecular characteristics of breast cancers analyzed (n = 33) a

From: Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors

Case Histotypeb T N Gc ER PR HER2 statusd Ki-67e p53 Doxo classf
BR1 IDC pT1c N1a G2 70% 70% Neg 10% Wt Responder
BR2 IDC pT2 pNx G2 90% 70% Neg 15% R280G Responder
BR3 IDC pT3 N1a G2 80% Neg Neg 20% Wt Non Responder
BR4 IDC pT1c N0 G2 80% 10% Pos 10% Wt Non Responder
BR5 IDC pT2 N3a G3 80% 90% Neg 20% Wt Non Responder
BR6 PC pT2 N2a G3 90% 5% Neg 10% Wt Responder
BR7 DLC pT3 N1 G3 90% 5% Neg 30% Wt Responder
BR8 IDC pT1c N1a G3 80% 70% Neg 25% Wt Responder
BR9 IDC pT1c N0 G2 90% 70% Neg 20% Wt Responder
BR10 IDC pT2 Nx G2 90% 95% Neg 15% Wt Responder
BR11 PC pT2 N0 G1 95% 95% Neg 10% Wt Responder
BR12 IDC pT1c N0 G3 95% 60% Neg 40% Wt Non Responder
BR13 IDC pT1c N0 G2 90% 85% Neg 15% Wt Non Responder
BR14 ILC pT3 N3a G3 25% 40% Pos 20% Wt Non Responder
BR15 IDC pT2 N0 G3 95% 20% Neg 10% Wt Responder
BR16 IDC pT1c N0 G2 95% Neg Neg 5% Wt Non Responder
BR17 IDC pT1c N0 G2 95% 95% Neg 20% Wt Non Responder
BR18 IDC pT3 N3 G3 Neg Neg Neg 45% Wt Responder
BR19 IDC pT2 N2 G3 90% 60% Pos 90% Wt Non Responder
BR20 IDC pT2 N3a G3 90% 2% Pos 10% Wt Responder
BR21 IDC pT2 Nx G3 90% 80% Neg 30% Wt Non Responder
BR22 IDC pT1c N0 G1 90% 90% Neg 5% Wt Responder
BR23 IDC pT1c Nx G2 90% 40% Neg 20% Wt Responder
BR24 IDC pT1c Nx G2 95% 95% Neg 5% Wt Responder
BR25 IDC pT2 N2a G1 90% 75% Neg 5% K132N Responder
BR26 IDC pT2 N1a G2 90% 70% Neg 10% Wt Non Responder
BR27 IDC pT1c N0 G3 90% 90% Neg 20% Wt Non Responder
BR28 IDC pT2 N1a G3 90% 10% Neg 30% Wt Responder
BR29 IDC pT1c N0 G3 90% Neg Neg 25% Wt Responder
BR30 IDC pT1c N1a G1 95% 95% Neg 5% Wt Responder
BR31 IDC pT1c N0 G3 Neg Neg Neg 40% Wt Non Responder
BR32 IDC pT2 N1a G3 95% 70% Neg 25% R248W Non Responder
BR33 IDC pT3 N3a G2 90% 80% Neg 10% Wt Responder
  1. aTumor stage according to TNM staging systems, grade, hormone or HER2 receptor status, tumor proliferation (percentage of Ki-67-positive cells), and p53 gene mutations are indicated along with our biological class related to the ex vivo doxorubicin treatment. All patients were M0, that is, no distant metastases were present at diagnosis. bIDC, invasive ductal carcinoma; PC, papillary carcinoma; DLC, ductal and lobular carcinoma; ILC, invasive lobular carcinoma.cG, tumor grade. dHER2 status was determined according to American Society of Clinical Oncology guidelines (2007). eKi-67 index as determined at diagnosis (approximate to the nearest 5%). fDoxorubicin class was assigned to breast cancers depending on the decrease of proliferating cells upon ex vivo doxorubicin treatment of at least 50% (Responders) or the maintenance of Ki-67-positive cells similar to control treated cultures (Non Responders).